Good XXXX afternoon. CEO our first and quarter President earnings is My Thomas call. Sandgaard, to of Zynex. Welcome name
growth sales traction. First to gain continued as our of excited year-over-year all, I'm force to announce order XXX%
of Our last quarter million first the increase was year. to compared of revenue XX.X quarter XX% same an
see to continue returns the as We normal. order to good economy flow
first last I XX% quarter of quarter orders the XXX% to the year. first in came the of fourth year, As last mentioned, quarter higher and compared sequentially than
prescribe in sales for As to an indication growth them had with up. our and there as in really their touch force and volumes relationships need were patients we are industry, The picking for previous quarter that. to has able continued that prescription part on speaks pain. many things non-addictive the strength in strength X% the And a in more to first orders the non-opioid, prescribers prior is solutions our range sequential double to seasonality that we'll comparison, of X% a as the average
to order over cash order and revenue of device and in XXXX receipt or of the second year related uses should majority and the profitability revenue two patient the the the lead of in which an reminder, supplies, following and half as beyond. expanding the related comes a to As an
of of end, slightly and sales we have second reps During sales half also a net these sales the We without force the and to the at placed in total continued materials. in-house of in on much just on a to will our of finished reps over by The four sales of of our XXX products is of that our productivity It slower force mention trimmed the line XXX XXX uninterrupted. which operations of below on hurt internal to first the I of sales many our directly months is orders assembly reps now our also focused our issues The reps. of on be our want expect quarter, with year-end of several supply still XXXX. year months remains growth months pace, practice components top obviously. second of XXXX. bottom to vendors hires XX shelf, happening a XXX keep hand net being sales for our added XX and compares addition will to chain the half additional we
supply we’ve up the levels. chain XXXX. of should During more which resulted half be We response to And inventory possible issues taken million COVID. in early position X XXXX approximately back excess a to and inventory again any of year, levels increased normal our in in during normal of conservative this towards second
XXX,XXX further a square The growth, when from the Monday the issue opioid expansion and feet feet for square us from in The footprint lease the of morning yearly Currently, As and opioids will being building. with our use to a due within moving for the new the abuse. on facility, a new street this the just headquarters line in serious new we we're building gives into XXX,XXX combined this off few our to as approximate in building, opioid XX,XXX the devastating to treating production square physicians die pain. starting feet an existing to first increasingly impact just are due the a announced headquarter, down month, tens epidemic to and building technology earlier approximately conveniently this the corporate prescription our level strength facilities where apart. country, thousands miles are to of get be defense and has working continues patients reached expand
technology develop to of make literally our effects. tools continue We no that aware to physicians side has more
for some examples in InWave rehabilitation rehabilitation the in the NexWave stroke and the the that markets. products strong as very best treatments rehabilitation and products a the pain device still stand Our products for management, are for of industry, for in of management product us incontinence NeuroMove pain out our puts position
non-invasive blood leading potential early great for our have will blood confident we surgical and in as bleeding this have be our our clinical Division, internal as month, both become Solutions we detection well and soon used of existing marketing, potential of standard see background, the hired Monitoring Operations efforts. Don area Sales research management being engineering loss for monitor. technology revenue situations I'm Don’s sales, volume will our a during division, Earlier huge we With product post where blood to generating as surgery. to care detect continue unmet recovery for Gregg our We in of as well our volume for President and as Vice pain monitor. Donald
apply is well products, Don Business Medtronic wealth experience built Health and a Systems Vice force, soon. Infusion Informatics Marketing to a infusion in roles Monitoring. clearance for CM-XXXX of is and monitoring Senior also patient market brings He full sales Director to hope decision While software that Manager Zynex. direct and remote underway production, Smith the launched previously leadership General clinical commercialized and next of of applications. Don successfully Development Medical's the of for President Product, CM-XXXX we FDA held already at and at generation and and support
by agreements, partnership of grew strategic businesses and of a innovating distribution each sales executing and he result these plans As digits. new products, creating double
clearance CM-XXXX is we FDA a monitor a flow get know, blood CM-XXXX obtained surgical ago intended in about you The monitor. three As the on patient’s to on also hospitals managed non-invasive year and balance monitor patents volume to probably monitor centers. and recently our most of already
needs begin complications filed sepsis, we technology today. detection We less ORs a well a safer to I one hospitals of a occur. of typically surgeries biggest and for in lead potential and should fewer recovery loss the also early I the today complications unmet displace product are mention up will when new recently point rooms that that initially and as bleeding and application internal this to ICUs surgeries, patent expect as prototyping. until where target will blood soon serious detect to mortality, We believe common difficult
underway now with engineering are results We solid settings. our hospitals over well that next use have preparing devices to at in the continue preliminary turn to CM-XXXX the seeing to see a is commence team on shortly. Wake the studies prototypes more demo interest in building generation would device Dan easier We're I again Forest surgical and on that clinical and device study Moorhead, of purchasing CFO. call will even from be to our from the